TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00557388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein/Amino Acids
Description: Casein Whey Leucine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
Study: NCT01419353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerate
Description: 2 mg P.O / day for 1-6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate
Description: 2 mg P.O / day for 1-6 days.
Study: NCT02797210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation
Study: NCT01034293

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low feeding frequency (3x)
Description: 3 meals a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High feeding frequency (14x)
Description: 14 meals a day
Study: NCT02014155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
Study: NCT03513172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
Description: The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)
Description: The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
Study: NCT02997488

Intervention type: DEVICE
Intervention: Pentax Airwayscope
Description: intubation using Pentax Airwayscope

Intervention type: DEVICE
Intervention: McGrath Videolaryngoscope
Description: intubation using McGrath Videolaryngoscope
Study: NCT00567268

Intervention type: DRUG
Intervention: Gabapentin
Description: GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration.
Study: NCT00470210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
Description: Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (Copegus®) 1600 mg/day
Description: Ribavirin (Copegus®) 1600 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin β (450 UI/kg/week)
Description: Epoetin β (450 UI/kg/week)
Study: NCT03255837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
Study: NCT01438021

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intraventricularly
Study: NCT00152139

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic Stem Cell Transplantation
Description: An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy and antibodies
Description: Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
Study: NCT01685190

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prostate alone IMRT
Description: Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate and pelvis IMRT
Description: Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
Study: NCT00149422

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NT-proBNP measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NT-proBNP measurements
Study: NCT01889056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epoetin beta)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride solution
Study: NCT04258371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 MG
Description: Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo once daily for 12 weeks
Study: NCT02952001

Intervention type: DRUG
Intervention: 4 mg CLS-TA Suprachoriodal Injection
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.

Intervention type: DRUG
Intervention: Sham procedure
Description: This drug was administered in the Parent study, CLS1001-301 (NCT02595398). No study treatments were administered during this observational extension study.
Study: NCT00720655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Fatty fish at least 4 meals per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Lean fish at least 4 meals per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention
Description: Control diet with lean meat and chicken.
Study: NCT01212250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
Study: NCT05385133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer guided condylar position
Description: post-osteotomy condylar position was performed using patient specific surgical guides and pre-bent plates

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual condylar position
Description: post-osteotomy condylar position was performed using the conventional manual method
Study: NCT01521897

Intervention type: BIOLOGICAL
Intervention: 7-valent vaccine injection
Description: For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
Study: NCT02261038

Intervention type: OTHER
Group type: OTHER
Intervention: Kanekasu radiographs
Description: No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
Study: NCT02616666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
Study: NCT01782118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus GG
Study: NCT02544217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT04576143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: i.v. 90 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: i.v. 90 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamid
Description: i.v. 600 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: i.v. 600 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: i.v. 100 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: i.v. 175 mg/m2
Study: NCT05165147

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04298463

Intervention type: DRUG
Intervention: Xydalba
Description: Drugs were administered i.v.

Intervention type: DRUG
Intervention: vancomycin, teicoplanin or daptomycin
Description: Drugs were administered i.v.
Study: NCT00638612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
Study: NCT01249937

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
Study: NCT01685710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTN patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: This arm will be a placebo patch to the active drug patch to blind the trial.
Study: NCT02415465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Block
Description: Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Block
Description: Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General
Description: General Intraoperative Anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal
Description: Spinal Intraoperative Anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal
Description: Spinal Intraoperative Anesthesia
Study: NCT00774865

Intervention type: PROCEDURE
Intervention: MIBI and CTA
Description: Rest and Stress MIBI and CT Angiography
Study: NCT00135759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: low dose naltrexone in addition to daily methadone taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: low dose naltrexone in addition to daily methadone taper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: 1 capsule/day for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 0.125 mg capsule/day for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 0.250 mg capsule/day for 6 days
Study: NCT03856658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Infusion Pump
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. The intervention is surgical placement of an HAI pump with subsequent delivery of FUDR via the pump in 28-day cycles. The primary tumor will be resected or ablated with irreversible electroporation at the time of HAI pump placement. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparinized Saline
Description: Together the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of Pancreatic adenocarcinoma. They have not yet been FDA approved for this indication, although they are both approved for other indications. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
Study: NCT00819260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel
Description: harmonic scalpel used to reduce breast on this side

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery
Description: Electrocautery used to reduce breast on this side
Study: NCT03696615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tabata Kettlebell Swing Workout
Description: See description of experimental arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: see description of control arm
Study: NCT00887250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: 50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: losartan
Description: 50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo to Losartan